B+
Bull case
20%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
BBNX
Beta BionicsDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-03
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+43.8
Score
AI commentary
The post-earnings tone is mixed-to-negative: operating metrics improved, but the unchanged revenue outlook, continued losses, and sharp July 30–31 price decline indicate limited investor confidence. Social coverage is unavailable, and analyst-revision evidence is thin, so this remains a monitoring setup rather than a high-conviction bullish thesis.
RankAlpha Sentiment Codex - 2026-08-03
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31eventQ2 growth and gross-margin improvement, but adverse post-print reactionMedium impact
Q2 revenue rose 38% year over year to $32.0 million, PBP revenue rose 153%, and gross margin reached 59.0%; full-year gross-margin guidance increased to 58.5%–59.5%, while revenue guidance was unchanged at $131–$136 million. The stock then fell about 6% on July 30 and 10% on July 31, indicating skepticism about earnings quality and forward profitability. [#SEC-8K-2026-07-29]
2026-09-30catalystPersistent losses, cash burn, and regulatory execution riskHigh impact
Despite revenue and margin gains, Q2 operating loss was $25.6 million, net loss was $23.4 million, and adjusted EBITDA was negative $17.7 million. Quality-system remediation related to the FDA Form 483 and Warning Letter, rising operating expenses, and delayed product milestones remain material risks. [#SEC-8K-2026-07-29]
2027-06-30catalystiLet type 2 diabetes pivotal trialHigh impact
Beta Bionics initiated enrollment for a U.S. pivotal trial in adults with type 2 diabetes and expects potential indication expansion around mid-2027, subject to FDA clearance. [#SEC-8K-2026-07-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-03 • Updated nightlySource: Internal modelMethodology